A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


June 14, 2013

Early Treatment May Do More Harm Than Good in Poor Regions

While U.S. treatment guidelines recommend universal treatment of HIV, the benefits of such a policy may not outweigh the costs in resource-poor areas around the globe. Three researchers from Johns Hopkins University published a paper in Clinical Infectious Diseases, arguing that the limited scope and inconsistent availability of antiretrovirals (ARVs), as well as diminished laboratory monitoring capacity, prompt ethical considerations about applying U.S. treatment standards to impoverished countries at this time.

Recommending early treatment for HIV in the United States is intended both to improve the health outlook of people living with the virus and to curb transmission to others. The increasing clarity of these benefits in recent years has been accompanied by a steady decline in the toxicity of newer ARVs. The Hopkins researchers posit that early use of ARVs in resource-poor settings still clearly benefits prevention efforts as well as people with HIV. However, they argue that because the available ARVs are more antiquated, people beginning therapy with high CD4 counts may put themselves at risk of side effects and toxicity. In addition, less effective therapies and inadequate or non-existent laboratory monitoring may lead people to develop drug resistance, thus potentially limiting future treatment options.

“Universal treatment should be the long-term goal, both for the benefit of those infected and for its effect on slowing and ultimately stopping the epidemic,” the authors write. “But in the enthusiasm for the benefits of ART, we must not lose sight of the glaring disparities among nations that stand as obstacles to the ethical implementation of ART.”

To read the study abstract, click here.

Search: HIV, antiretroviral treatment, universal treatment, resource-poor settings, Clinical Infectious Diseases, Johns Hopkins University.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.